These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

149 related items for PubMed ID: 1801535

  • 21. Modification of dopamine D2 receptor activity by pergolide in Parkinson's disease: an in vivo study by PET.
    Linazasoro G, Obeso JA, Gómez JC, Martínez M, Antonini A, Leenders KL.
    Clin Neuropharmacol; 1999; 22(5):277-80. PubMed ID: 10516878
    [Abstract] [Full Text] [Related]

  • 22. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.
    Torstenson R, Hartvig P, Långström B, Westerberg G, Tedroff J.
    Ann Neurol; 1997 Mar; 41(3):334-40. PubMed ID: 9066354
    [Abstract] [Full Text] [Related]

  • 23. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
    Dentresangle C, Veyre L, Le Bars D, Pierre C, Lavenne F, Pollak P, Guerin J, Froment JC, Brousolle E.
    Mov Disord; 1999 Nov; 14(6):1025-30. PubMed ID: 10584682
    [No Abstract] [Full Text] [Related]

  • 24. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease.
    Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente-Fernandez R, Calne DB, Stoessl AJ.
    Ann Neurol; 2000 Apr; 47(4):493-503. PubMed ID: 10762161
    [Abstract] [Full Text] [Related]

  • 25. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
    Hansen AK, Knudsen K, Lillethorup TP, Landau AM, Parbo P, Fedorova T, Audrain H, Bender D, Østergaard K, Brooks DJ, Borghammer P.
    Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
    [Abstract] [Full Text] [Related]

  • 26. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study.
    Ouchi Y, Kanno T, Okada H, Yoshikawa E, Futatsubashi M, Nobezawa S, Torizuka T, Sakamoto M.
    Ann Neurol; 1999 Nov; 46(5):723-31. PubMed ID: 10553989
    [Abstract] [Full Text] [Related]

  • 27. PET measurements of dopaminergic pathways in the brain.
    Perlmutter JS, Moerlein SM.
    Q J Nucl Med; 1999 Jun; 43(2):140-54. PubMed ID: 10429509
    [Abstract] [Full Text] [Related]

  • 28. Are "on-off" effects during chronic L-dopa treatment due to faulty feedback control of the nigrostriatal dopamine pathway?
    Carlsson A.
    J Neural Transm Suppl; 1983 Jun; 19():153-61. PubMed ID: 6321646
    [Abstract] [Full Text] [Related]

  • 29. Brain dopaminergic mechanisms in Parkinson's disease evaluated by positron emission tomography.
    Aquilonius SM, Långström B, Tedroff J.
    Acta Neurol Scand Suppl; 1989 Jun; 126():55-9. PubMed ID: 2618594
    [Abstract] [Full Text] [Related]

  • 30. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study.
    Brooks DJ, Playford ED, Ibanez V, Sawle GV, Thompson PD, Findley LJ, Marsden CD.
    Neurology; 1992 Aug; 42(8):1554-60. PubMed ID: 1641153
    [Abstract] [Full Text] [Related]

  • 31. Dopaminergic function and progression of Parkinson's disease: PET findings.
    Biju G, de la Fuente-Fernández R.
    Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 4():S38-40. PubMed ID: 20123555
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness.
    Hornykiewicz O.
    Neurodegener Dis; 2008 Dec; 5(3-4):114-7. PubMed ID: 18322366
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. The use of PET in Parkinson's disease.
    Shinotoh H, Calne DB.
    Brain Cogn; 1995 Aug; 28(3):297-310. PubMed ID: 8546856
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Motor disturbance and brain functional imaging in Parkinson's disease.
    Brooks DJ.
    Eur Neurol; 1997 Aug; 38 Suppl 2():26-32. PubMed ID: 9387800
    [Abstract] [Full Text] [Related]

  • 40. Pathophysiology of L-dopa-induced abnormal involuntary movements.
    Agid Y, Bonnet AM, Ruberg M, Javoy-Agid F.
    Psychopharmacology Suppl; 1985 Aug; 2():145-59. PubMed ID: 2987904
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.